Weight-Loss Drugs Target Root of Cravings

Blockbuster GLP-1 drugs, widely used for diabetes and obesity, may offer a new avenue for preventing and mitigating substance use disorders, according to a recent large-scale analysis. The study, published in The BMJ, examined electronic health records of over 600,000 U.S. Veterans Affairs patients with diabetes.

Researchers found that individuals treated with GLP-1 agonists such as Ozempic and Mounjaro exhibited a lower incidence of developing addictions to alcohol, nicotine, cocaine, and opioids compared to those on different diabetes medications. The medications demonstrated potential in reducing the risk of addiction by 14% to 25% across various substances.

Furthermore, for patients already diagnosed with substance use disorders, the initiation of GLP-1 drugs correlated with substantial reductions in severe outcomes. These included a 31% lower risk of emergency department visits, a 26% decrease in hospitalizations, a 25% reduction in suicidal thoughts or attempts, a 39% lower risk of overdose, and a notable 50% decrease in mortality.

While the study highlights a significant association, experts caution that it is observational and does not prove causation. Randomized controlled trials are still needed to confirm these promising findings. Nevertheless, addiction specialists are encouraged by the potential for GLP-1s to offer a novel therapeutic tool, potentially addressing the root biological drivers of cravings and addiction.